Marché mondial du fébuxostat – Tendances et prévisions de l'industrie jusqu'en 2029

Analyse et perspectives du marché mondial du fébuxostat

Le marché du fébuxostat devrait connaître une croissance exponentielle au cours de la période de prévision 2022-2029. Data Bridge Market Research analyse le marché pour s'attendre à une croissance à un TCAC de 7,9 % au cours de la période de prévision mentionnée ci-dessus et devrait atteindre 1 662,16 millions USD d'ici 2029.

Le fébuxostat est un inhibiteur de la xanthine oxydase utilisé pour traiter l'hyperuricémie chronique chez les personnes souffrant de goutte qui ne répondent pas à l'allopurinol ou ne le tolèrent pas. Le fébuxostat diminue la quantité d'acide urique produite dans votre corps. Les symptômes de la goutte sont causés par une accumulation d'acide urique. Le fébuxostat est un médicament qui aide les personnes souffrant de goutte à empêcher leur taux d'acide urique d'augmenter trop haut. Le fébuxostat est exclusivement prescrit aux personnes qui ne peuvent pas prendre d'allopurinol ou dont l'allopurinol a cessé d'agir. Le comprimé oral de fébuxostat est un médicament de marque. Il n'en existe pas de version générique. Uloric est le nom de marque de ce médicament. Le fébuxostat est un médicament qui se prend une fois par jour. La majorité des patients commencent par un comprimé de 40 mg par jour. Il peut être augmenté à 80 mg par jour si nécessaire. Le fébuxostat est un médicament qui peut être pris avec ou sans nourriture. Des antiacides peuvent être pris avec le fébuxostat. À des températures comprises entre 15 °C et 30 °C, le fébuxostat doit être conservé à l’abri de la lumière directe du soleil.

L'augmentation de l'incidence de la goutte dans le monde sera un moteur majeur de l'expansion du marché du fébuxostat. En outre, l'augmentation de la population gériatrique et l'augmentation des dépenses de santé augmenteront la demande pour le marché du fébuxostat. En outre, l'augmentation de la demande de diverses industries d'utilisation finale et les initiatives gouvernementales et non gouvernementales croissantes sont les facteurs qui élargiront le marché du fébuxostat. D'autres facteurs, notamment l'urbanisation rapide et la sensibilisation croissante, auront un impact positif sur le taux de croissance du marché. Un autre facteur important qui accélérera le taux de croissance du marché du fébuxostat est l'augmentation du niveau de revenu disponible.

Moreover, the rise in the research and development activities and emerging new markets will provide beneficial opportunities for the febuxostat market in the forecast period of 2022-2029.

However, high cost of the drug and side effects associated with febuxostat such loss of appetite, dizziness, fever, chills, skin rash, nausea, vomiting, and others. All these factors hamper the febuxostat market’s growth.

On the other hand, the dearth of awareness will further challenge the febuxostat market in the forecast period mentioned above.

This febuxostat market report provides details of new recent developments, trade regulations, import export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the febuxostat market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Global Febuxostat Market Scope and Market Size

The febuxostat market is segmented on the basis of strength, drug class, application, demographic, dosage form, end-users and distribution channel. The growth amongst these segments will help you analyze meager growth segments in the industries, and provide the users with valuable market overview and market insights to help them in making strategic decisions for identification of core market applications.

• On the basis of strength, the febuxostat market is segmented into 40mg, 80mg, 20mg, and 120mg
• On the basis of drug class, the febuxostat market is segmented into antihyperuricemic agents and others.
• On the basis of application, the febuxostat market is segmented into acute gout, chronic gout and others.
• On the basis of demographic, the febuxostat market is segmented into adult, and pediatric.
• On the basis of dosage form, the febuxostat market is segmented into oral tablet and others.
• On the basis of end-users, the febuxostat market is segmented into clinic, hospital and others.

The febuxostat market is also segmented on the basis of distribution channel into hospital pharmacy, retail pharmacy and online pharmacy.

Febuxostat Market Country Level Analysis

Febuxostat market is analyzed and market size information is provided by the country, strength, drug class, application, demographic, dosage form, end-users and distribution channel as referenced above.

The countries covered in the febuxostat market report are the U.S., Canada, Mexico, Brazil, Argentina, Peru, Rest of South America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Hungary, Lithuania, Austria, Ireland, Norway, Poland, Rest of Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Vietnam, Rest of Asia-Pacific, Saudi Arabia, U.A.E, Egypt, Israel, Kuwait, South Africa, Rest of Middle East and Africa.

North America dominates the febuxostat market due to the presence of major key players, high disposable income and well-developed healthcare infrastructure in this region. Asia-Pacific is expected to grow during the forecast period of 2022-2029 due to the increasing research and development activities, improvements in the infrastructure of healthcare sector and growing government support in this region.

The country section of the report also provides individual market impacting factors and changes in regulations in the market domestically that impacts the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, disease epidemiology and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of sales channels are considered while providing forecast analysis of the country data.

Patient Epidemiology Analysis

Febuxostat market also provides you with detailed market analysis for patient analysis, prognosis and cures. Prevalence, incidence, mortality, adherence rates are some of the data variables that are available in the report. Direct or indirect impact analysis of epidemiology to market growth are analysed to create a more robust and cohort multivariate statistical model for forecasting the market in the growth period.

Competitive Landscape and Global Febuxostat Market Share Analysis

Febuxostat market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, company strengths and weaknesses, product launch, clinical trials pipelines, product approvals, patents, product width and breadth, application dominance, technology lifeline curve. The above data points provided are only related to the companies’ focus related to febuxostat market research.

Français Certains des principaux acteurs opérant sur le marché du fébuxostat sont Takeda Pharmaceutical Company Limited., Lupin, Sun Pharmaceutical Industries Ltd., Alembic Pharmaceuticals Limited, Hikma Pharmaceuticals PLC, Mylan NV, HENGRUI USA, Teijin Pharma Limited, Macleods Pharmaceuticals Ltd., Schwitz Biotech, DivineSavior.in, APINO PHARMA CO., LTD., Emcure Pharmaceuticals Limited, UNIMARK REMEDIES, Bayeebio Biotech (Shanghai) Co., Ltd., et FIS – Fabbrica Italiana Sintetici SpA, entre autres.

SKU-67502